Diagnostics company Accelerate Diagnostics Inc (NASDAQ:AXDX) said on Sunday that it expects total revenues of approximately USD1.8m for the fourth quarter ending 31 December 2018.

This marks a decline when compared with total revenues of USD2.1m in the fourth quarter of 2017.

In the full-year 2018, the company anticipates total revenue to be USD5.7m over total revenue of USD4.2m for full-year 2017.

Net cash, excluding financing, is expected to be about USD14.1m for the Q4 and USD64.1m for full-year 2018.

Commercially contracted instruments in the US rose by 117 in the fourth quarter, doubling the US commercial installed base. Commercially contracted instruments in EMEA escalated by 16 during the same period.